Novel Hepatitis B Virus Capsid-Targeting Antiviral that Aggregates Core Particles and Inhibits Nuclear Entry of Viral Cores

An estimated 240 million are chronically infected with hepatitis B virus (HBV), which can lead to liver disease, cirrhosis, and hepatocellular carcinoma. Currently, HBV treatment options include only nucleoside reverse transcriptase inhibitors and the immunomodulatory agent interferon alpha, and the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ACS Infect Dis
Main Authors: Huber, Andrew D., Pineda, Dallas L., Liu, Dandan, Boschert, Kelsey N., Gres, Anna T., Wolf, Jennifer J., Coonrod, Emily M., Tang, Jing, Laughlin, Thomas G., Yang, Qiongying, Puray-Chavez, Maritza N., Ji, Juan, Singh, Kamalendra, Kirby, Karen A., Wang, Zhengqiang, Sarafianos, Stefan G.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6510658/
https://ncbi.nlm.nih.gov/pubmed/30582687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsinfecdis.8b00235
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados